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ABSTRACT 
Antimicrobial photodynamic inactivation (aPDI) uses photosensitizers (PSs) and harmless 
visible light to generate reactive oxygen species (ROS) and kill microbes. Multidrug efflux 
systems can moderate the phototoxic effects of PSs by expelling the compounds from cells. 
We hypothesized that increasing intracellular concentrations of PSs by inhibiting efflux with 
a covalently attached efflux pump inhibitor (EPI) would enhance bacterial cell phototoxicity 
and reduce exposure of neighbouring host cells to damaging ROS. In this study, we tested the 
hypothesis by linking NorA EPIs to methylene blue (MB) and examining the 
photoantimicrobial activity of the EPI-MB hybrids against the human pathogen methicillin-
resistant Staphylococcus aureus (MRSA). Photochemical/photophysical and in vitro 
microbiological evaluation of sixteen hybrids carrying four different NorA EPIs attached to 
MB via four linker-types identified INF55-(Ac)en-MB 12 as a lead. Compound 12 showed 
increased uptake into S. aureus cells and enhanced aPDI activity and wound healing effects 
(relative to MB) in a murine model of an abrasion wound infected by MRSA. The study 
supports a new approach for treating localized multidrug-resistant MRSA infections and 
paves the way for wider exploration of the EPI-PS hybrid strategy in aPDI. 
 
Keywords: antimicrobial photodynamic inactivation; photosensitizer-efflux pump inhibitor 
hybrid; methicilllin resistant Staphylococcus aureus; reactive oxygen species; 
bioluminescence wound infection model 
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 Methicillin-resistant Staphylococcus aureus (MRSA) infections have emerged as a 
major medical threat over the past two decades.
1
 Despite a downward mortality trend in 
Europe, MRSA remains a major cause of serious skin and soft-tissue infections,
2-4
 
community-acquired pneumonia and catheter-related bloodstream infections, and is 
responsible for the majority of recurrent infections in immunocompromised patients.
5
 Several 
classes of antibiotics have been used to treat MRSA infections over the years, including the 
topically applied mupirocin, later generation β-lactams, broad spectrum tetracyclines, 
linezolid, the lipopeptide daptomycin, the glycopeptide vancomycin and the recently 
approved lipoglycopeptides telavancin, oritavancin and dalbavancin.
6
 Some of these 
antibiotics have, or will likely become, ineffective against MRSA due to the development of 
resistance, thus ensuring an ongoing need for new antibiotics and treatment strategies 
targeting this significant human pathogen.
7
 
 Multidrug resistance often arises due to transmembrane efflux systems, which serve to 
pump noxious compounds from microbial cells.
8
 Efflux systems in Gram-positive cocci (e.g. 
MRSA) tend to exhibit broad and overlapping substrate specificities, with many compounds 
(e.g. antibiotics, monovalent and divalent biocides, intercalating dyes, quaternary ammonium 
salts, diamidines, biguanidines and plant secondary metabolites) acting as efflux pump 
substrates.
9
 Efflux-mediated resistance in Staphylococci has been attributed to pumps from 
the chromosomally encoded Major Facilitator Superfamily (MFS: NorA, NorB, NorC, 
MdeA),
10
 the Multi-Antimicrobial Extrusion protein family (MATE: mepA),
10
 Small 
Multidrug Resistance proteins (SMR: SepA)
11
 and the plasmid encoded systems QacA, QacB 
and Tet(K).
12-14
 The NorA pump has been extensively studied in S. aureus, including  as a 
discovery target for small molecule efflux pump inhibitors (EPIs).
15
 
Photodynamic therapy (PDT) is a light-based technology that harnesses the combined 
power of visible or near-visible light and photosensitizers (PSs) to kill cells. PSs are typically 
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non-toxic, highly conjugated aromatic molecules that exert photodynamic activity through 
reactions with molecular oxygen.
16
 Illumination with light of a suitable wavelength and 
reaction of the excited-state PSs with O2 generates reactive oxygen species (ROS) (e.g. 
singlet oxygen 
1
O2 and hydroxyl radicals •OH) that cause non-specific cell damage and 
death. While PDT has been widely explored in the treatment of cancer
17
 and age-related 
macular degeneration,
18
 antimicrobial photodynamic inactivation (aPDI) has only more 
recently emerged as a powerful sterilization technique and promising treatment for localized 
bacterial infections.
19
 The phenothiazinium PSs methylene blue (MB) and toluidine blue O 
(TBO), for example, are used for photodynamic sterilization of blood products and aPDI oral 
cavity disinfection.
20-23
 
 Efflux pumps have been shown to moderate bacterial cell killing during aPDI with 
MB, apparently by lowering intracellular MB concentrations and associated (intracellular) 
ROS.
24
 This suggested that combination approaches, where MB is co-administered with a 
small molecule efflux pump inhibitor (EPI), should potentiate aPDI by increasing 
intracellular MB and associated ROS, thus triggering more damaging intracellular 
photodynamic reactions. Additionally, better localization of PSs to the bacterial intracellular 
space would reduce the damaging effects of the ROS generated in solution on neighboring 
host cells at infection sites, which could aid wound healing. Studies by Tegos et al. 
demonstrated that combinations of NorA EPIs and MB (a well-characterised NorA substrate) 
show enhanced PDI of S. aureus relative to MB alone.
25
 
 We previously reported an efflux pump inhibitor-antibacterial hybrid strategy for 
addressing NorA efflux-mediated resistance in S. aureus. The prototype hybrid (SS14) 
containing berberine, a weak antibacterial natural product and NorA substrate,
26, 27
 covalently 
linked to the synthetic NorA EPI 5-nitro-2-phenylindole (INF55), showed potent antibacterial 
activity, rapidly accumulated in S. aureus cells and was more effective than co-administered 
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berberine/INF55 combinations in a Caenorhabditis elegans model of enterococcal 
infection.
28
 Analogues of SS14 showed remarkably similar effects indicating that significant 
structural changes could be introduced into the hybrids without diminishing antibacterial 
action.
29, 30
 
 Phenothiazinium photosensitizers (e.g. MB) are amphipathic, planar, polycyclic 
aromatic cations and physicochemically similar to the quaternary ammonium aromatic 
alkaloid berberine. The structural and physicochemical similarities between berberine and 
MB, combined with the known susceptibility of both compounds to NorA-mediated efflux,
27
 
suggested that a NorA EPI-MB hybrid strategy might be successfully applied in aPDI of S. 
aureus. We hypothesized that the hydrophobic/cationic EPI-MB hybrids would, in a similar 
fashion to MB, spontaneously enter S. aureus cells due to the negative membrane potential.
31
 
Unlike MB, however, the hybrids would resist efflux due to the attached NorA EPI. The 
higher resulting intracellular hybrid concentrations would amplify intracellular ROS 
(following illumination) leading to enhanced lethality compared to MB, whose photodynamic 
reactions are restricted by efflux mostly to the cell exterior (Figure 1, Top). Importantly, EPI-
MB hybrids would be more attractive for clinical development than PS/EPI inhibitor 
combinations due to the simpler scientific (i.e. active pharmaceutical ingredient/formulation 
optimization, administration and delivery) and regulatory approval pathway for single agent 
therapeutics. 
  This study aimed to test the hypothesis by: (1) identifying a lead EPI-MB hybrid that 
shows increased uptake into S. aureus cells and enhanced in vitro PDI of S. aureus relative to 
MB alone, and (2) demonstrating that the selected lead shows enhanced PDI activity (relative 
to MB) in a murine MRSA localized wound infection model. A focussed 16-member EPI-
MB hybrid library was rationally designed and synthesised and its members systematically 
screened using photochemical, photophysical and in vitro microbiological assays with S. 
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aureus. Compound INF55(Ac)en-MB 12 emerged as the lead hybrid and was subsequently 
examined alongside MB for in vivo aPDI effects against MRSA. Experiments probing the 
mechanism of enhanced PDI activity with INF55(Ac)en-MB 12 were also explored. 
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Figure 1. Proposed mechanism for enhanced PDI of S. aureus cells by EPI-MB hybrids 
relative to MB (Top). Structures of hybrids 1-16 (Bottom). 
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RESULTS AND DISCUSSSION 
Library design and synthesis 
At the outset of the study it was not known if linking NorA EPIs to MB would 
adversely impact EPI activities or the photochemical properties of MB. A medicinal 
chemistry approach was therefore adopted, where a focused library of 16 hybrids was 
synthesized with members containing four known NorA EPIs attached to MB via four 
different linker types. The structural variants were designed to systematically scan EPI-MB 
chemical space and increase the likelihood of identifying a lead hybrid for in vivo studies. 
When designing EPI-MBs, we rationalized that only minimal structural modifications 
should be introduced at the phenothiazinium moiety in order to maintain the photosensitizer 
properties of MB. Such changes were considered less likely to impact ROS generation via the 
Type I (radical formation) and Type II (singlet oxygen formation) photochemical reactions of 
MB.
32
 In the first compound series (1,3,5,7,9,11,13,15), the N-(CH3)2 group at the C-7 
position of MB was replaced with a piperazine-based linker to direct EPIs away from the MB 
moiety. The second series (2,4,6,8,10,12,14,16) employed more flexible N,N’-
dimethylethylenediamine-based linkers. Four S. aureus NorA efflux pump inhibitors 
(reserpine,
33 
pterostilbene,
34
 INF55
35
 and INF271
35
) were appended to the linkers using both 
N-alkyl and N-acyl attachments as a way of systematically varying hybrid polarity and 
basicity. The structures of 1-16 are shown in Figure 1 (Bottom) and full details of their 
syntheses are provided in the Supporting Information, Section 1 ̶ Chemistry. 
 
UV/Visible Spectroscopy 
 The absorption properties of the MB chromophore in hybrids 1-16 were probed using 
UV/visible spectroscopy. MB shows strong absorption bands between 550-700 nm, 
displaying an intense maximum at λmax1 = 668 nm and a shoulder at λmax2 = 609 nm.
36
 Large 
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differences in wavelength and/or extinction coefficients at λmax1 and λmax2 for hybrids 
compared to MB would indicate that the structural modifications had altered the absorption 
properties of the chromophore. Hybrids exhibiting such changes were considered less likely 
to maintain the photosensitizer and aPDI properties of MB. UV/Visible spectra (Supporting 
Information, Supplementary Figure 5) and wavelength/extinction coefficient data (Supporting 
Information, Supplementary Figure 6) revealed that the λmax1 and λmax2 absorption bands 
varied little among MB and the hybrids, confirming that attachment of EPIs to MB had not 
significantly impacted the UV/visible absorption properties of the chromophore. 
 
Photo-Induced 
1
O2 and •OH Production by Hybrids 
 Effective aPDI with hybrids requires that sufficient ROS be produced from the 
compounds following illumination. Photo-induced 
1
O2 and •OH production by hybrids 1-16 
was examined by measuring the fluorescence emitted from co-dissolved ROS fluorescent 
reporter probes singlet oxygen sensor green (SOSG) and 3’-p-(hydroxyphenyl) fluorescein 
(HPF), respectively, following illumination with 652 nm red light. It has been shown that 
ROS generation by phenothiazinium PSs does not differ in the presence or absence of cells.
37
 
The 
1
O2 and •OH data generated were thus relevant to the study’s cell-based experiments 
(vide infra). Measurements for MB and hybrids 1-16 were performed in 96-well plates, plots 
of fluorescence versus light fluence generated (Supporting Information, Supplementary 
Figure 10) and the differences in fluorescence quantum yields relative to MB (%Φ∆) were 
calculated (Figure 2). 
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Figure 2. Fluorescence quantum yields (Φ∆) from SOSG (
1
O2) and HPF (•OH) probes 
following illumination of compounds 1-16 with 652 nm red light (0-12 J/cm
2
). Data are 
reported as %Φ∆ ± SEM relative to MB from three independent experiments. 
 
 Generation of 
1
O2 and •OH from all hybrids was lower than for MB. For reserpine-
EPI-MBs 1-4 the levels ranged between 22-55% (of MB), while for Pterostilbene-EPI-MBs 
5-8 the levels were less than 21%. INF55-EPI-MBs 9-12 and INF271-EPI-MB 16 showed 
greater than ca 2-fold higher 
1
O2 production than •OH, with
1
O2 generation by 9 (65%) being 
the strongest of all the hybrids. Compound 12 (hereafter referred to as INF55(Ac)en-MB) 
generated the second highest 
1
O2 levels (60%) and was the strongest producer of •OH (30%) 
among the INF55-EPI-MB series. Hybrid 16 from the INF271-EPI-MB series exhibited the 
third highest levels of 
1
O2 production (55%). 
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In vitro PDI of MRSA USA300 
For cell-based in vitro and in vivo experiments it was necessary to identify a non-toxic 
vehicle for solubilizing hybrids in aqueous media. Testing the aqueous solubility of 
reserpine-EPI-MB 3 (selected after noting its particularly poor aqueous solubility) using 
common detergents identified Cremophor EL
®
 (CrEL) as a promising lead (Supporting 
Information, Supplementary Figure 11). CrEL was selected for use in all experiments after 
confirming it did not change photodynamic 
1
O2 production by MB (relative to PBS/MeOH, 
Supporting Information, Supplementary Figure 10) and because of its reportedly low 
toxicity.
38
 
Hybrids 1-16 were screened alongside MB for dose-dependent PDI of MRSA 
USA300 over the concentration range of 1-20 µM (652 nm red light, 6 J/cm
2
). The complete 
data set is provided in the Supporting Information, Supplementary Figure 13. A summary of 
the activities observed at the highest concentration tested (20 µM) is shown in Figure 3. In 
dark control experiments, no significant toxicity was observed for any of the hybrids or MB 
and there was no difference between the dark toxicity of MB formulated in CrEL or 
PBS/MeOH (Supporting Information, Supplementary Figure 12). A 2 log10 reduction in 
survival was observed with MB (20 µM) in PBS upon light application, with an additional 1 
log10 of killing seen when MB was formulated in CrEL. INF55(Ac)en-MB 12 showed the 
strongest aPDI activity, producing a 3 log10 greater killing effect than MB/CrEL at 20 µM. 
INF271-EPI-MBs 13 and 14 also showed higher activity than MB/CrEL, while reserpine-
EPI-MB 4 and INF55-EPI-MB 10 produced equivalent killing effects (to MB/CrEL). The 
remaining hybrids all showed either lower or no activity. 
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Figure 3. Photodynamic inactivation of MRSA USA300 by MB and hybrids 1-16 following 
illumination with 652 nm red light at 6 J/cm
2
. All compounds were present at 20 µM. Data 
represent the mean of three independent experiments ± SEM. 
 
PDI and uptake studies with S. aureus isogenic NorA efflux mutants 
Previous studies with knockout (NorA-, K1758), wild-type (WT, 8325-4) and 
overexpressing (NorA++, K2361) S. aureus isogenic NorA efflux mutants showed that NorA 
expression correlates with reduced PDI by MB, due to the NorA-mediated efflux reducing 
intracellular MB concentrations and associated intracellular ROS.
25
 Three hybrids exhibiting 
both significant ROS production and potent PDI of the MRSA USA300 strain (i.e. 10, 
INF55(Ac)en-MB 12 and 14) were selected for studies with the S. aureus NorA efflux 
mutants to examine the effects of this pump on hybrid PDI activity. 
13 
 
PDI of the S. aureus mutants was measured over the concentration range 0-160 µM at 
a constant light fluence. In dark control experiments, MB showed some dose-dependent 
toxicity at concentrations above 20 µM, especially against the NorA- and NorA++ strains. 
The hybrids were generally less toxic than MB at equivalent concentrations (Supporting 
Information, Supplementary Figure 14). Upon application of 652 nm red light (10 J/cm
2
), MB 
(20 µM) caused a 2.9 log10 reduction in survival of the NorA- strain, and 2.2 log10 and 1.8 
log10 reductions in the WT and NorA++ strains, respectively (Figure 4), in agreement with a 
previous report.
24
 
The NorA++ strain showed a pronounced sensitivity to 10 and INF55(Ac)en-MB 12, 
exhibiting an 8 log10 reduction in survival at concentrations above 40 µM. The NorA- strain 
also showed high sensitivity to INF55(Ac)en-MB 12, while higher concentrations of 10 (80 
µM) were required to produce an 8 log10 reduction in this strain. The three strains were 
uniformly less sensitive to the INF271-based hybrid 14. The WT strain was the least sensitive 
towards all three hybrids at most concentrations. 
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Figure 4. PDI of S. aureus NorA efflux mutants by: (a) MB, (b) 10, (c) INF55(Ac)en-MB 12 
and (d) 14 following illumination with 652 nm red light at 10 J/cm
2
. Data represent the mean 
± SEM from three independent experiments. 
 
Cellular uptake of 10, INF55(Ac)en-MB 12 and 14 by the three S. aureus NorA 
mutants was examined using a fluorescence-based assay. Uptake of MB was highest in the 
NorA- strain (3.7 x 10
9
 molecules/cell), reduced in the WT (1 x 10
9
 molecules/cell) and 
15 
 
lowest in the NorA++ strain (0.5 x 10
9
 molecules/cell, Figure 5), consistent with 
susceptibility to NorA efflux.
25
 Uptake of the three hybrids was similar and higher than MB 
in all strains. Hybrid uptake varied little among the strains despite the differences in NorA 
expression, suggesting that unlike MB the compounds are not susceptible to NorA efflux. 
 
 
Figure 5. Uptake of MB and hybrids 10, INF55(Ac)en-MB 12 and 14 by S. aureus isogenic 
NorA efflux mutants. All compounds were present at 20 µM. Data represent the mean ± SEM 
from three independent experiments. One-tailed t tests comparing MB uptake into each strain 
to uptake of each hybrid showed significant differences (***P < 0.001). 
 
Inhibition of the NorA efflux pump 
Having established that 10, INF55(Ac)en-MB 12 and 14 accumulate in S. aureus cells 
and that they were not substrates for NorA, experiments were conducted to establish whether 
the hybrids also blocked the NorA pump. This was done by comparing PDI of NorA++ S. 
aureus cells by MB alone, MB in combination with the NorA EPIs INF55 and INF271 and 
MB in the presence of three hybrid surrogates, 30, 31 and 32. The surrogates corresponded to 
EPIs INF55 and INF271 functionalized with the (N-Boc-protected)-linker groups present in 
16 
 
10, 12 and 14, respectively, with no MB attached (See Supporting Information, Section 1 ̶ 
Chemistry for the structures of 30-32). 
NorA++ S. aureus cells were treated with MB (20 µM) both alone and in combination 
with the EPIs (10 µM), illuminated with 652 nm red light  (0-16 J/cm
2
) and the survival 
fractions determined (Figure 6). For MB alone, a 2 log10 greater kill was observed at the 
maximum fluence (16 J/cm
2
) compared to the dark control. In agreement with previous 
findings,
25
 introduction of INF55 and INF271 potentiated MB PDI activity, affording an 
additional 4 log10 killing effect at 16 J/cm
2
. PDI with MB in the presence of 30-32 was 
virtually unchanged from that observed with INF55 and INF271, confirming that the 
derivatized EPIs showed equivalent NorA inhibitory effects. Taken together, these results 
demonstrate that increased cellular uptake of 10, INF55(Ac)en-MB 12 and 14 (relative to 
MB) into S. aureus cells arises from the direct inhibition of the NorA pump (by the appended 
EPIs) and not solely because the hybrids evade NorA-mediated efflux. 
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Figure 6. PDI of S. aureus NorA++
 
cells by MB (20 µM) and MB in combination with 
INF55, INF271 and derivatized EPIs 30-32 (all 10 µM). Data represent the mean ± SEM 
from three independent experiments. 
 
Murine MRSA wound infection aPDI model 
INF55(Ac)en-MB 12 was selected as the lead hybrid for in vivo studies where the 
goal was to establish whether the superior S. aureus cell uptake and in vitro PDI activity 
observed with 12 against MRSA relative to MB translated to increased efficacy in a whole-
animal MRSA infection. Hybrid 12 was assessed alongside MB using the murine needle 
back-scratch wound abrasion aPDI model developed by Dai et al.
39
 This model employs 
bioluminescent MRSA Xen30
40, 41
 for facile infection monitoring and reflects the initial 
stages of the wound infection process.
39
 
Immunosuppressed female BALB/c mice were divided into 5 cohorts, each containing 
6 animals. Group A served as the negative control (no compound + light), Group B as the 
MB dark control (MB + no light) and Group C received MB + light. Group D served as the 
dark control for INF55(Ac)en-MB 12 (12 + no light) and Group E received 12 + light. Back-
18 
 
scratch wounds were introduced onto animals and inoculated with MRSA Xen30. Compound 
treatments were added by direct application to infection sites, red light (652 nm) was applied 
in 5 doses over 20 min and bioluminescence images were captured after each dose. A 
summary of the treatment cohorts and the experimental protocol is provided in the 
Supporting Information, Supplementary Figure 15. Representative images from animals in 
Groups A-E during the initial ‘light-treatment’ phase of the experiment are provided in the 
Supporting Information, Supplementary Figure 16. The quantitative wound bioluminescence 
data are presented in Figure 7(a). 
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Figure 7. (a) Bioluminescence of MRSA Xen30-infected mouse wounds during initial ‘light-
treatment’ phase. Data represent the mean (± SEM) normalized relative luminescence units 
(RLU) emanating from the wounds of 6 mice in each group. (b) Ten day post-treatment 
monitoring of infection site bioluminescence. Data represent the mean ± SEM (n = 6) for 
each cohort. (c) Photographs of infection sites in Groups A-E at Days 4-6 post-treatment. 
In the absence of compound (Group A) the bioluminescence signal decreased less 
than 20%, confirming that the bacterial load was stable over the 20 min ‘light-treatment’ 
period. For the MB dark control (Group B) a 36% reduction in luminescence was observed. 
20 
 
Application of light to the MB–treated cohort (Group C) produced a light dose-dependent 
PDI response. After 2 min of light application (12 J/cm
2
) bioluminescence was reduced by 
45%, which increased to 70% after 6 min (36 J/cm
2
) and became undetectable after 20 min 
(120 J/cm
2
). For the INF55(Ac)en-MB 12 dark control (Group D) a 24% reduction in 
bioluminescence was seen after 20 min. A remarkable 98% reduction was observed with 
INF55(Ac)en-MB 12 after applying light for just 2 min (12 J/cm
2
) and total loss of the 
bioluminescence signal was observed after 6 min. 
Post-treatment monitoring of infection sites was performed for 10 days by capturing 
daily bioluminescence images (Supporting Information, Supplementary Figure 17). The 
bioluminescence signals were quantified and the data are presented in Figure 7(b). A rebound 
in the bacterial load, indicated by a ~1.6-fold increase in bioluminescence, was observed in 
the control groups (Group A, B and D) after Day 1 and their infections were resolved by Day 
10. For the MB + light cohort (Group C), a smaller (1.3-fold) rebound was observed after 1 
day and the infections were resolved within 7 days. For the INF55(Ac)en-MB 12 + light 
cohort (Group E), no rebound in the bacterial load was observed and the infections were 
completely resolved within 4 days. As shown in Figure 7(c), control Groups A, B and D 
exhibited minimal signs of healing on Days 4-6. The MB + light cohort (Group C) showed 
visible signs healing by Day 6, while animals treated with INF55(Ac)en-MB 12 + light 
(Group E) were healed by Day 4. 
 
CONCLUSIONS 
The need for continuous development of new therapeutic approaches targeting MRSA 
is high since: (i) the evolutionary adaptability of MRSA to antibiotic pressure has proven to 
be a remarkably successful survival strategy for this important human pathogen
42
 and (ii) use 
of conventional broad spectrum antibiotics is a risk factor for increasing resistance, especially 
21 
 
in healthcare facilities.
43
 Treatment of MRSA infections with antibiotics, including recently 
approved compounds
44
 and new agents coming through the pipeline,
45
 will likely afford only 
temporary solutions due to the inevitable development of resistance. In contrast, aPDI offers 
an attractive and easy-to-apply non-antibiotic alternative for treating localized MRSA 
infections that limits the development of resistance because of its multi-target/non-specific 
mode of action. aPDI approaches are predicted to have much longer effective clinical 
lifetimes than antibiotics.
46
 In an era where there is an urgent need to identify anti-infective 
solutions beyond traditional antibiotics, aPDI offers extraordinary promise. Despite this, there 
have been surprisingly few clinical studies exploring aPDI
46-53
. 
This study explored the hypothesis that hybrid molecules, consisting of a NorA EPI 
covalently tethered to MB via a non-cleavable linker, could show increased aPDI activity 
relative to MB against MRSA. The hypothesis was founded on the idea that attaching the 
NorA EPI would increase intracellular concentrations of MB and associated intracellular 
ROS, leading to enhanced phototoxic effects. We predict that clinical use of such 
photoantimicrobials could provide effective aPDI treatments at low compound/light doses, 
thus reducing potential for ROS-mediated damage to host tissues. This is because 
concentrating ROS inside bacteria would place a protective (cell membrane) barrier between 
the phototoxic species and host cells. Preserving host tissues around infection sites should 
also provide benefits for wound healing through photobiomodulation effects.
54, 55
 
UV/Visible absorption spectra of the 16 hybrids showed that the wavelengths and 
extinction coefficients of bands arising from the MB chromophore remained largely 
unchanged (relative to MB), indicating that the absorption properties of MB were not affected 
by the appended structures. INF55-EPI-MBs 10 and 12 and INF271 EPI-MBs 14 and 16 
showed the strongest PDI of MRSA and uptake of 10, 12 and 14 by the S. aureus NorA panel 
was much greater than MB and varied little across the phenotypes. Together these findings 
22 
 
indicated that EPI-MBs are not substrates for the NorA efflux pump. PDI experiments with 
MB in combination with INF55, INF271 and INF55- and INF271-containing compounds that 
lacked an appended MB group confirmed that these three hybrids also block the NorA pump. 
The lead hybrid INF55(Ac)en-MB 12 was advanced to in vivo studies to establish 
whether its superior in vitro effects relative to MB translated to a vertebrate animal MRSA 
aPDI infection model. During the light treatment phase of the experiment INF55(Ac)en-MB 
12 produced a more potent and rapid light-dose response than MB, while during the post-
treatment monitoring period the bacterial re-growth observed with MB was not seen with 12. 
More rapid clearance of bacteria was also observed and, crucially, wound healing occurred 
much earlier following treatment with INF55(Ac)en-MB 12 than MB. 
This study demonstrates that attaching an EPI to a photosensitizer can increase aPDI 
efficacy, both in vitro and in vivo. The findings pave the way for pre-clinical assessment of 
aPDI with INF55(Ac)en-MB 12 in topical MRSA infections and support wider exploration of 
the EPI-PS approach as a method for treating drug resistant localized infections. As our 
fundamental understanding of microbial efflux pumps matures and our arsenal of EPI 
scaffolds expands, especially against Gram-negative pathogens, numerous opportunities will 
likely emerge for creating effective new EPI-PS hybrid photoantimicrobials. 
 
METHODS 
Chemistry. Complete details of the syntheses of hybrids 1-16 and all synthetic intermediates 
are provided in the Supporting Information, Section 1 ̶ Chemistry. 
 
UV/Visible Spectroscopy. UV/Visible spectra were recorded over the wavelength range 250-
750 nM using 10 µM solutions of MB and 1-16 in MeOH at 23 
o
C using a Shimadzu UV-
1700 PharmaSpec Spectrophotometer spectrometer. 
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1
O2 and •OH Experiments. Solutions of MB and hybrids 1-16 (50 µM, 85 µL) in phosphate-
buffered saline (PBS, pH 11) were added to 96-well plates (Fisher Scientific, USA), followed 
by 40 µL of SOSG (5 µM) or HPF (5 µM) probes in PBS. D2O (40 µL) was added to each 
well to increase the life-time of •OH and 
1
O2
56, 57
 and MeOH (40 µL) was added as co-
solvent. Plates were illuminated with red light (652 nm) for times corresponding to 0-12 
J/cm
2
 fluence and plots of fluorescence versus fluence produced (Supporting Information, 
Supplementary Figure 10). A schematic summary of the experiments is provided in the 
Supporting information, Supplementary Figure 9. 
A noncoherent light source (LC122; LumaCare, London, UK) with 30 nm-band-pass 
filters at ranges of 652 ± 15 nm was used for illumination. The total power output from the 
fibre bundle was 300 mW. Plates were arranged to give irradiance of 100 mW/cm
2
. The 
power (P) in watts was equal to the energy (E) in joules, divided by the illumination time (t) 
in seconds: 
P(W) = E(J) / t(s) 
       So 
Watt/cm
2
 = joule/cm
2
 per second 
A 30 sec  illumination at irradiance 100 mW/cm
2
 over a 3 cm
2
 area provides a fluence of 
1000 mJ/cm
2
, or 1 J/cm
2
. Fluence was proportionally increased by extending the period of 
illumination. A microplate spectrophotometer was used in “slow kinetic” mode for detecting 
fluorescence. For SOSG, emission was measured at 505 nm following excitation at 525 nm (2 
nm monochromator band pass). For HPF, fluorescence emission was measured at 525 nm 
after excitation at 492 nm (2 nm monochromator band pass). 
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Fluorescence quantum yield is defined as the ratio of the number of photons emitted 
from a fluorophore to the number of photons absorbed. Relative fluorescence quantum yields 
in the SOG and HPF experiments were determined by comparing the observed fluorescence 
for hybrids 1-16 to MB, which produces known quantum yields under the experimental 
conditions (Φ∆ SOG = 0.52, Φ∆ HPF = 0.46). Quantum yields for the hybrids in each assay 
relative to MB were calculated using the equation: 
 
Where Int is the area under the emission curve (on a wavelength scale), A is optical density at 
the excitation wavelength and n is the refractive index of the solvent. The subscript MB refers 
to the respective values for methylene blue. Since the same energies of light and the same 
solvents were used for MB and hybrids, the relative quantum yields could be obtained by 
measuring the area under the fluorescence curves (Supporting Information, Supplementary 
Figure 10) and dividing by the area under the MB curve. For each fluorescence curve, a best-
fit trend line was obtained using polynomial regression and the relative integration calculated 
over the fluence range 0-10 J/cm
2 
for SOG and 0-12 J/cm
2
 for HPF.  Further details regarding 
these experiments can be found in the Supporting Information, Section 3 − 
1
O2 and •OH 
experiments. 
  
Bacterial strains and culture conditions. Community Associated (CA)-MRSA (strain 
USA300, human isolate/Clinical Microbiology, Massachusetts General Hospital, MA, USA) 
was used for in vitro PDI screening of hybrids 1-16. Mouse adapted S. aureus wild-type 
strain 8325-4 (Hamblin Lab), isogenic NorA efflux knockout strain (NorA-, SA-1758, 
Φ
∆ =    
Φ
∆MB  
 X X X 
Int 
Int
MB
 
1-10
-A
 
1-10
-A
MB
  n
2
 
n
MB
2
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Hamblin Lab) and NorA overexpressing strain (NorA++, SA-K2378, Hamblin Lab)
58-60
 were 
used for PDI and uptake studies with 10, INF55(Ac)en-MB 12 and 14. The bioluminescent 
MRSA Xen30 (LuxABCDE operon) strain used in the animal infection model was obtained 
from the Dai Lab, Wellman Center for Photomedicine, Massachusetts General Hospital, MA, 
USA.
40
 Bacterial cells were cultured in Mueller–Hinton Broth (MHB) and growth was 
monitored using a Shimadzu Mini 1240 spectrometer at 600 nm (OD600). 
 
In vitro PDI studies with S. aureus MRSA USA300 and NorA efflux mutants. MRSA 
USA300 cells (10
8
 cfu/mL) were incubated with hybrids 1-16 or MB (0-20 µM) for 30 min at 
room temperature in 96-well plates before being illuminated with 652 nm light (6 J/cm
2
). 
Wells were stirred constantly during illumination to ensure bacteria did not settle and were 
adequately mixed for sampling. Aliquots were removed, 10-fold serially diluted in PBS to 
provide 10
−1
 to 10
−6
 dilutions, streaked horizontally across square brain heart infusion agar 
plates and incubated overnight at 37 °C. Colony forming units were counted and survival 
fractions determined, as described by Jett et al.
61
 Data are reported as log10 (reduction in 
survival fraction). Identical procedures were employed for PDI studies with 10, 
INF55(Ac)en-MB 12 and 14 against the NorA isogenic mutants, except for use of 10 J/cm
2
 
fluence. For dark controls, the same procedures were used without the illumination step. 
 
Cell uptake studies with S. aureus NorA efflux mutants. Uptake experiments were based on 
the procedure reported by Tegos et al.
25
 Briefly, bacterial suspensions (10
8
 cfu/mL) were 
incubated with compound (20 µM) in the dark at room temperature for 30 min. The cell 
suspensions were centrifuged (9,000 × g, 1 min) and the supernatant aspirated. The bacterial 
pellet was washed twice with sterile PBS (1 mL), centrifuged (9,000 × g, 1 min) and the 
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supernatant aspirated. The pellet was digested in 3 mL of 0.1 M NaOH containing 1% 
sodium dodecyl sulfate (SDS) for 48 h to give a homogenous solution. Fluorescence of the 
solution was measured using a spectrofluorimeter (FluoroMax3; SPEX Industries, Edison, 
NJ) with excitation at 650 nm and emission over the range 655-720 nm. Fluorescence 
calibration curves were generated from serial dilutions of each compound in 0.1 M NaOH/1% 
SDS. If necessary, cell digest solutions were diluted with 0.1 M NaOH/1% SDS until 
fluorescence fell within the linear region of the calibration curve. Cellular uptake was 
calculated by dividing the amount of compound (nmol) in the dissolved pellet by the number 
of cfu obtained from serial dilutions and converting to molecules/cell using Avogadro's 
number.  
 
NorA efflux pump inhibition studies. Compounds 30 and 31, corresponding to the (Boc-
protected) INF55-linker groups found in 10 and 12, respectively, and 32, corresponding to the 
(Boc-protected) INF271-linker region in 14, were intermediates in the synthesis of the parent 
hybrids (Supporting Information, Section 1 ̶ Chemistry). NorA++ S. aureus cells were 
incubated for 30 min at room temperature with INF55, INF271, 10, 12 or 14 (all 10 µM) and 
MB (20 µM) in 96-well plates before illumination with increasing fluences of 652 nm red 
light (0-16 J/cm
2
). Aliquots were removed and the survival fractions determined, as described 
above for the in vitro PDI studies. 
 
Murine MRSA wound infection model. All procedures were approved by the Subcommittee 
on Research Animal Care at the Massachusetts General Hospital (MA, USA) and were in 
accordance with the guidelines of the National Institutes of Health (NIH). Stocks of MB and 
INF55(Ac)en-MB 12 were freshly prepared as CrEL/PBS micellar solutions to final 
concentrations of 200 µM (Supporting Information, Section 4(b) Preparation of CrEL 
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micellar solutions). Bioluminescent MRSA Xen30
40
 cultures were grown overnight in brain 
heart infusion (BHI) media at 37 °C with 100 rpm orbital shaking. Bacterial growth was 
assessed using an Evolution 300 UV/Vis Spectrophotometer (Thermo Scientific, Waltham, 
MA, USA). Cultures of 0.8 optical density at 600 nm (OD600) corresponded to 10
8
 cfu/mL. 
Cells were washed with PBS, re-suspended in PBS to a density of 10
8
 cfu/mL and used for 
wound inoculations. 
Adult 7-8 week old female BALB/c mice weighing 17-21 g (Charles River 
Laboratories, Wilmington, MA, USA) were housed one per cage with access to food and 
water ad libitum while being maintained on a 12-hour light-dark cycle at 21 °C (relative 
humidity range 30-70%). Mice were immunosuppressed with intraperitoneal (i.p.) 
cyclophosphamide injections
62
 4 days (150 mg/kg i.p.) and 1 day (100 mg/kg i.p.) prior to 
MRSA Xen30 inoculation. On the day of inoculation, mice were anesthetized with i.p. 
injections of ketamine (100 mg/kg)/xylazine (10mg/kg) cocktail and their dorsal surfaces 
shaved. Skin abrasion wounds were introduced onto the dorsal surfaces by using a 28-gauge 
needle (Micro-Fine IV, Becton Dickinson, Franklin Lakes, NJ) to scratch 6 x 6 cross-hatch 
lines in a square covering 1.0 cm
2
. The scratches were applied such that only the stratum 
corneum and upper-layer of the epidermis were damaged. Five minutes after wounding a 40 
µL aliquot was drawn from the 10
8
 cfu/mL suspension of MRSA Xen 30 in PBS and spread 
evenly over the wound area using a micropipette. Bioluminescence images were captured 
immediately after inoculation. Thirty minutes after inoculation, MB and INF55(Ac)en-MB 12 
(40 µL of 200 µM stock solutions) were introduced to infection sites on animals from Groups 
B-E using a micropipette and a second bioluminescence image was captured. Fifteen minutes 
after compound addition (to allow binding/penetration into cells) a third image was captured 
(Time = 0). Mice were then illuminated with 652 nm light in 2, 4, 8, 4 and 2 min aliquots 
over a 20 min period, corresponding to fluences of 12, 36, 84, 108 and 120 J/cm
2
. 
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Bioluminescence images were captured after each light dose.  For the negative control Group 
A and dark controls Groups B and D, images were captured at the equivalent times post-
inoculation. Bioluminescence images were captured daily for 10 days following treatment to 
monitor clearance of the infection and daily photographs were taken (Nikon Coolpix L20 
camera) to record wound healing.  
A noncoherent light source (LC122; LumaCare, London, UK) with interchangeable 
fibre bundles and 30 nm band-pass filters (652 ± 15 nm) was used for light application. 
Power output from the fibre bundle was 300 mW, with spots positioned at the required 
distance from animals to give an irradiance of 100 mW over the 1.0 cm
2
 wound area. 
Bioluminescence images were captured using a Hamamatsu Photonics KK (Bridgewater, NJ) 
imaging system,
39
 consisting of an intensified charge-coupled-device (ICCD), camera 
(C2400-30H; Hamamatsu), camera controller, imaging box, image processor (C5510-50; 
Hamamatsu) and color monitor (PVM 1454Q; Hamamatsu). Mice were placed on an 
adjustable stage in the specimen chamber and infected areas positioned directly under the 
camera. Light-emitting diodes were mounted inside the imaging box to supply light for 
dimensional imaging. The setup allowed a grayscale background image of each mouse to be 
taken. Luminescence emanating from wounds was captured using an integration time of 2 
min at the maximum setting on the image-intensifier control module. ARGUS software 
(Hamamatsu) was used to present luminescence as false-colour images (pink most intense, 
blue least intense) superimposed on the grayscale background and to calculate relative 
luminescence units (RLU) from total pixel values. 
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